Table 1.
Baseline features of asymptomatic and symptomatic patients with COVID‐19
| Total (N = 214) | Asymptomatic (N = 26) | Symptomatic (N = 188) | P‐value | |
|---|---|---|---|---|
| Age, median (IQR) a | 51 (39–59) | 42 (31–51) | 52 (41–60) | 0.001 |
| ≤ 60 years | 168 (79%) | 25 (96%) | 143 (76%) | 0.019 |
| > 60 years | 46 (21%) | 1 (4%) | 45 (24%) | |
| Gender | ||||
| Male | 86 (40%) | 9 (35%) | 77 (40%) | 0.54 |
| Female | 128 (60%) | 17 (65%) | 111 (60%) | |
| Signs or symptoms | ||||
| Body temperature | 38.1 (36.7–38.4) | 36.5 (36.4–36.7) | 38.1 (37.8–38.5) | <0.001 |
| Any symptom | 188 (88%) | 0 (0%) | 188 (100%) | <0.001 |
| Fever | 144 (67%) | 0 (0%) | 144 (77%) | <0.001 |
| Cough | 141 (66%) | 0 (0%) | 141 (75%) | <0.001 |
| Fatigue | 45 (21%) | 0 (0%) | 45 (24%) | 0.005 |
| Chest tightness | 23 (11%) | 0 (0%) | 23 (12%) | 0.12 |
| Myalgia | 10 (5%) | 0 (0%) | 10 (5%) | 0.48 |
| Diarrhoea | 9 (4%) | 0 (0%) | 9 (5%) | 0.54 |
| Headache | 8 (4%) | 0 (0%) | 8 (4%) | 0.60 |
| Dyspnoea | 7 (3%) | 0 (0%) | 7 (4%) | 1.0 |
| Palpitations | 6 (3%) | 0 (0%) | 6 (3%) | 1.0 |
| Chills | 5 (2%) | 0 (0%) | 5 (3%) | 1.0 |
| Comorbidities | ||||
| Any | 42 (20%) | 4 (15%) | 38 (20%) | 0.43 |
| Hypertension | 21 (10%) | 2 (8%) | 19 (10%) | 0.86 |
| Diabetes | 11 (5%) | 1 (4%) | 10 (5%) | 1.0 |
| Cardiovascular diseases | 7 (3%) | 0 (0%) | 7 (4%) | 0.60 |
| Chronic pulmonary disease | 7 (3%) | 1 (4%) | 6 (3%) | 1.0 |
| Cancers | 6 (3%) | 1 (4%) | 5 (3%) | 0.57 |
| Gastrointestinal diseases | 3 (1%) | 0 (0.0) | 3 (2%) | 1.0 |
| Mental diseases | 2 (1%) | 0 (0.0) | 2 (1%) | 1.0 |
| Laboratory biomarkers b | ||||
| White blood cells (×10⁹ L−1) | 5.35 (4.67–6.40) | 6.10 (5.06–6.58) | 5.23 (4.57–6.37) | 0.027 |
| Lymphocytes (×10⁹ L−1) | 1.59 (1.27–1.91) | 1.86 (1.49–2.09) | 1.52 (1.26–1.87) | 0.017 |
| Eosinophils (×10⁹ L−1) | 0.08 (0.05–0.15) | 0.13 (0.07–0.22) | 0.07 (0.05–0.14) | 0.02 |
| Neutrophils (×10⁹ L−1) | 3.29 (2.62–4.05) | 3.50 (2.82–4.13) | 3.22 (2.61–4.02) | 0.41 |
| Monocytes (×10⁹ L−1) | 0.34 (0.29–0.43) | 0.36 (0.30–0.43) | 0.34 (0.29–0.43) | 0.49 |
| Basophils (×10⁹ L−1) | 0.01 (0.01–0.02) | 0.01 (0.01–0.02) | 0.01 (0.01–0.02) | 0.10 |
| Red blood cells (×1012 L−1) | 4.44 (4.08–4.77) | 4.60 (4.46–4.83) | 4.36 (4.04–4.73) | 0.029 |
| Haemoglobin (g L−1) | 136 (128–145) | 138 (132–146) | 135 (126–145) | 0.33 |
| Platelets (×10⁹ L−1) | 232 (195–279) | 221 (205–270) | 237 (194–281) | 0.79 |
| C‐reactive protein (mg L−1) | 1.23 (0.45–4.01) | 0.84 (0.22–1.87) | 1.38 (0.49–5.28) | 0.06 |
a
Interquartile ranges (IQR) of continuous variables are shown in the table.
b
Results were measured by the first biomarker tests within the first‐week hospitalisation. Normal ranges of biomarkers are listed in Supplementary table 1.